China’s ascendant drug industry is no monolith, despite how it’s often described by Western competitors, pundits, and policymakers. The country is home to scores of companies with diverging ambitions, founded last year or last century, each vying for attention and capital amid a domestic scientific renaissance and a geopolitical standoff.
It’s complicated. To help make sense of it, STAT and the risk intelligence platform WireScreen on Monday published China’s Biotech Powerhouse 25, a ranking of the country’s most valuable publicly traded firms that tracks the varying strategies — and fortunes — of the world’s rapidly growing new medicine chest.
